Biomarin Historical Balance Sheet

BMRN Stock

USD 71.44 1.39 1.91%

Trend analysis of Biomarin Pharmaceutical balance sheet accounts such as Short Long Term Debt Total of 578.5 M, Other Current Liabilities of 367.6 M or Total Current Liabilities of 317.7 M provides information on Biomarin Pharmaceutical's total assets, liabilities, and equity, which is the actual value of Biomarin Pharmaceutical to its prevalent stockholders. By breaking down trends over time using Biomarin Pharmaceutical balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Biomarin Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biomarin Pharmaceutical is a good buy for the upcoming year.

Biomarin Pharmaceutical Inventory

1.29 Billion

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

About Biomarin Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Biomarin Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Biomarin Pharmaceutical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Biomarin Pharmaceutical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Biomarin currently owns. An asset can also be divided into two categories, current and non-current.

Biomarin Pharmaceutical Balance Sheet Chart

At this time, Biomarin Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 28th of March 2025, Net Receivables is likely to grow to about 693.6 M, while Short and Long Term Debt Total is likely to drop about 578.5 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Biomarin Pharmaceutical assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Biomarin Pharmaceutical books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Biomarin Pharmaceutical balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Biomarin Pharmaceutical are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Biomarin Pharmaceutical's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 28th of March 2025, Net Receivables is likely to grow to about 693.6 M, while Short and Long Term Debt Total is likely to drop about 578.5 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	1.1B	1.1B	602.7M	578.5M
Total Assets	6.4B	6.8B	7.0B	7.3B

Short Long Term Debt Total Total Assets

Biomarin Pharmaceutical balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock Total Equity	Short Term Investments	Short Term Debt
Total Assets		0.56	0.8	0.7	0.99	0.96	0.03	-0.11	0.4	0.79	0.98	0.53	0.71	0.95	0.78	0.64	0.95	0.88	0.98	0.78	0.96	0.97	0.41	0.75	0.46	-0.14
Short Long Term Debt Total	0.56		0.35	0.62	0.46	0.66	0.35	-0.51	0.5	0.64	0.53	0.12	0.85	0.38	0.77	0.8	0.37	0.41	0.59	0.83	0.46	0.57	0.42	0.72	0.54	0.37
Other Current Liab	0.8	0.35		0.32	0.84	0.64	-0.2	0.42	-0.19	0.7	0.77	0.44	0.46	0.83	0.47	0.43	0.84	0.74	0.68	0.44	0.86	0.8	-0.09	0.43	0.14	-0.34
Total Current Liabilities	0.7	0.62	0.32		0.62	0.78	0.43	-0.47	0.73	0.43	0.7	0.19	0.68	0.63	0.75	0.46	0.62	0.51	0.74	0.85	0.63	0.66	0.52	0.72	0.53	0.23
Total Stockholder Equity	0.99	0.46	0.84	0.62		0.92	-0.09	0.01	0.31	0.79	0.97	0.55	0.63	0.97	0.7	0.54	0.98	0.91	0.95	0.68	0.97	0.97	0.31	0.68	0.37	-0.22
Property Plant And Equipment Net	0.96	0.66	0.64	0.78	0.92		0.2	-0.36	0.6	0.72	0.96	0.44	0.76	0.87	0.85	0.71	0.86	0.81	0.99	0.87	0.88	0.92	0.58	0.82	0.58	-0.06
Net Debt	0.03	0.35	-0.2	0.43	-0.09	0.2		-0.64	0.38	-0.36	0.13	-0.25	0.28	-0.16	0.34	0.48	-0.16	-0.34	0.11	0.54	-0.07	-0.09	0.55	0.29	0.65	0.04
Retained Earnings	-0.11	-0.51	0.42	-0.47	0.01	-0.36	-0.64		-0.84	0.02	-0.15	0.17	-0.47	0.09	-0.51	-0.5	0.11	0.08	-0.29	-0.57	0.06	-0.06	-0.76	-0.51	-0.65	-0.35
Accounts Payable	0.4	0.5	-0.19	0.73	0.31	0.6	0.38	-0.84		0.24	0.42	0.17	0.52	0.26	0.63	0.41	0.25	0.28	0.54	0.66	0.26	0.35	0.79	0.64	0.5	0.4
Cash	0.79	0.64	0.7	0.43	0.79	0.72	-0.36	0.02	0.24		0.7	0.48	0.71	0.77	0.62	0.51	0.76	0.85	0.75	0.55	0.76	0.87	0.11	0.61	0.2	0.17
Non Current Assets Total	0.98	0.53	0.77	0.7	0.97	0.96	0.13	-0.15	0.42	0.7		0.57	0.66	0.9	0.78	0.67	0.91	0.81	0.97	0.8	0.93	0.91	0.51	0.75	0.46	-0.16
Non Currrent Assets Other	0.53	0.12	0.44	0.19	0.55	0.44	-0.25	0.17	0.17	0.48	0.57		0.17	0.46	0.36	0.32	0.48	0.5	0.47	0.3	0.5	0.44	0.37	0.35	-0.13	0.21
Cash And Short Term Investments	0.71	0.85	0.46	0.68	0.63	0.76	0.28	-0.47	0.52	0.71	0.66	0.17		0.55	0.86	0.82	0.55	0.51	0.75	0.88	0.61	0.74	0.46	0.85	0.72	0.18
Net Receivables	0.95	0.38	0.83	0.63	0.97	0.87	-0.16	0.09	0.26	0.77	0.9	0.46	0.55		0.63	0.39	0.99	0.93	0.9	0.6	0.94	0.96	0.18	0.6	0.29	-0.21
Common Stock Shares Outstanding	0.78	0.77	0.47	0.75	0.7	0.85	0.34	-0.51	0.63	0.62	0.78	0.36	0.86	0.63		0.84	0.61	0.59	0.82	0.92	0.65	0.73	0.63	0.99	0.57	0.16
Non Current Liabilities Total	0.64	0.8	0.43	0.46	0.54	0.71	0.48	-0.5	0.41	0.51	0.67	0.32	0.82	0.39	0.84		0.39	0.35	0.67	0.86	0.5	0.56	0.65	0.8	0.68	0.08
Inventory	0.95	0.37	0.84	0.62	0.98	0.86	-0.16	0.11	0.25	0.76	0.91	0.48	0.55	0.99	0.61	0.39		0.93	0.9	0.59	0.97	0.96	0.17	0.58	0.29	-0.24
Other Current Assets	0.88	0.41	0.74	0.51	0.91	0.81	-0.34	0.08	0.28	0.85	0.81	0.5	0.51	0.93	0.59	0.35	0.93		0.84	0.5	0.86	0.91	0.14	0.58	0.13	-0.11
Other Stockholder Equity	0.98	0.59	0.68	0.74	0.95	0.99	0.11	-0.29	0.54	0.75	0.97	0.47	0.75	0.9	0.82	0.67	0.9	0.84		0.82	0.91	0.95	0.53	0.8	0.55	-0.1
Total Liab	0.78	0.83	0.44	0.85	0.68	0.87	0.54	-0.57	0.66	0.55	0.8	0.3	0.88	0.6	0.92	0.86	0.59	0.5	0.82		0.66	0.71	0.68	0.89	0.71	0.18
Property Plant And Equipment Gross	0.96	0.46	0.86	0.63	0.97	0.88	-0.07	0.06	0.26	0.76	0.93	0.5	0.61	0.94	0.65	0.5	0.97	0.86	0.91	0.66		0.94	0.23	0.63	0.35	-0.22
Total Current Assets	0.97	0.57	0.8	0.66	0.97	0.92	-0.09	-0.06	0.35	0.87	0.91	0.44	0.74	0.96	0.73	0.56	0.96	0.91	0.95	0.71	0.94		0.27	0.7	0.45	-0.11
Intangible Assets	0.41	0.42	-0.09	0.52	0.31	0.58	0.55	-0.76	0.79	0.11	0.51	0.37	0.46	0.18	0.63	0.65	0.17	0.14	0.53	0.68	0.23	0.27		0.63	0.58	0.22
Common Stock Total Equity	0.75	0.72	0.43	0.72	0.68	0.82	0.29	-0.51	0.64	0.61	0.75	0.35	0.85	0.6	0.99	0.8	0.58	0.58	0.8	0.89	0.63	0.7	0.63		0.54	0.16
Short Term Investments	0.46	0.54	0.14	0.53	0.37	0.58	0.65	-0.65	0.5	0.2	0.46	-0.13	0.72	0.29	0.57	0.68	0.29	0.13	0.55	0.71	0.35	0.45	0.58	0.54		-0.08
Short Term Debt	-0.14	0.37	-0.34	0.23	-0.22	-0.06	0.04	-0.35	0.4	0.17	-0.16	0.21	0.18	-0.21	0.16	0.08	-0.24	-0.11	-0.1	0.18	-0.22	-0.11	0.22	0.16	-0.08

Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.8B	6.0B	6.4B	6.8B	7.0B	7.3B
Short Long Term Debt Total	1.1B	1.1B	1.1B	1.1B	602.7M	578.5M
Other Current Liab	289.2M	329.4M	330.3M	351.6M	350.1M	367.6M
Total Current Liabilities	492.5M	539.8M	588.9M	1.2B	607.0M	317.7M
Total Stockholder Equity	4.1B	4.3B	4.6B	5.0B	5.7B	5.9B
Property Plant And Equipment Net	1.0B	1.0B	1.1B	1.1B	1.0B	1.1B
Net Debt	426.0M	491.8M	358.5M	340.6M	(340.1M)	(323.1M)
Retained Earnings	(861.6M)	(925.7M)	(789.2M)	(621.6M)	(194.7M)	(204.4M)
Accounts Payable	191.4M	193.0M	231.2M	315.5M	235.4M	160.3M
Cash	649.2M	587.3M	724.5M	755.1M	942.8M	990.0M
Non Current Assets Total	3.5B	3.7B	3.6B	3.9B	3.8B	3.9B
Non Currrent Assets Other	142.2M	151.8M	176.2M	125.5M	251.4M	264.0M
Cash And Short Term Investments	1.1B	1.0B	1.3B	1.1B	1.1B	619.4M
Net Receivables	448.4M	373.4M	461.3M	633.7M	660.5M	693.6M
Common Stock Shares Outstanding	191.7M	182.9M	189.0M	191.6M	196.7M	130.9M
Liabilities And Stockholders Equity	5.8B	6.0B	6.4B	6.8B	7.0B	7.3B
Non Current Liabilities Total	1.2B	1.2B	1.2B	713.0M	724.0M	594.3M
Inventory	698.5M	776.7M	894.1M	1.1B	1.2B	1.3B
Other Current Assets	129.9M	110.4M	104.5M	141.4M	201.5M	211.6M
Other Stockholder Equity	5.0B	5.2B	5.4B	5.6B	5.8B	6.1B
Total Liab	1.7B	1.7B	1.8B	1.9B	1.3B	912.0M
Property Plant And Equipment Gross	1.0B	1.8B	1.9B	1.9B	1.9B	2.0B
Total Current Assets	2.3B	2.3B	2.8B	3.0B	3.2B	3.4B
Accumulated Other Comprehensive Income	(16.1M)	14.4M	(3.9M)	(38.6M)	61.7M	64.7M
Intangible Assets	417.3M	388.7M	338.6M	294.7M	255.3M	245.9M
Common Stock Total Equity	178K	180K	182K	184K	211.6K	126.8K
Short Term Investments	416.2M	426.6M	567.0M	318.7M	194.9M	274.0M
Short Term Debt	11.8M	10.5M	10.4M	502.7M	7.6M	7.2M
Common Stock	182K	184K	186K	189K	191K	136.1K
Other Assets	612.0M	1.6B	1.6B	1.6B	1.8B	1.9B
Long Term Debt	1.1B	1.1B	1.1B	593.1M	595.1M	557.4M
Property Plant Equipment	1.0B	1.0B	1.0B	1.1B	1.3B	1.3B
Current Deferred Revenue	152K	7.0M	711K	4.6M	1.4M	1.4M
Other Liab	98.1M	174.3M	113.7M	73.5M	84.5M	81.8M
Net Tangible Assets	2.5B	3.5B	3.7B	4.1B	4.7B	4.9B
Retained Earnings Total Equity	(1.7B)	(1.7B)	(861.6M)	(925.7M)	(833.1M)	(874.8M)
Long Term Debt Total	830.4M	486.2M	1.1B	1.1B	1.2B	730.7M
Capital Surpluse	4.7B	4.8B	5.0B	5.2B	6.0B	3.7B
Long Term Investments	285.5M	507.8M	333.8M	611.1M	521.2M	368.0M

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

6.449

Earnings Share

2.25

Revenue Per Share

15.018

Quarterly Revenue Growth

0.156

Return On Assets

0.0515

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Historical Balance Sheet

Biomarin Pharmaceutical Inventory

1.29 Billion

About Biomarin Balance Sheet Analysis

Biomarin Pharmaceutical Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Biomarin Pharmaceutical balance sheet Correlations

Biomarin Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biomarin Pharmaceutical balance sheet Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.99	Property Plant And Equipment Net
Inventory	+ 0.99	Net Receivables
Common Stock Total Equity	+ 0.99	Common Stock Shares Outstanding
Non Current Assets Total	+ 0.98	Total Assets
Other Stockholder Equity	+ 0.98	Total Assets

Accounts Payable	- 0.84	Retained Earnings
Intangible Assets	- 0.76	Retained Earnings
Short Term Investments	- 0.65	Retained Earnings
Retained Earnings	- 0.64	Net Debt
Total Liab	- 0.57	Retained Earnings
Common Stock Total Equity	- 0.51	Retained Earnings